FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310989660> ?p ?o ?g. }

• W4310989660 endingPage "5869" @default.
• W4310989660 startingPage "5869" @default.
• W4310989660 abstract "Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is a strong prognostic factor in breast cancer (BC). The aim of this study was to investigate whether semiquantitative parameters derived from baseline [18F]Fluorodeoxyglucose ([18F]FDG) positron emission computed tomography/computed tomography (PET/CT) could predict pCR after NAC and survival outcomes in patients affected by different molecular subtypes of BC. We retrospectively retrieved patients from the databases of two Italian hospitals (Centre A: University Hospital of Ferrara; Centre B: University of Padua) meeting the following inclusion criteria: (1) diagnosis of BC; (2) history of NAC; (3) baseline [18F]FDG PET/CT performed before the first cycle of NAC; (4) available follow-up data (response after NAC and survival information). For each [18F]FDG PET/CT scan, semiquantitative parameters (SUVmax, SUVmean, MTV and TLG) related to the primary tumor (B), to the reference lesion for both axillary (N) and distant lymph node (DN), and to the whole-body burden of disease (WB) were evaluated. Patients enrolled were 133: 34 from centre A and 99 from centre B. Patients' molecular subtypes were: 9 luminal A, 49 luminal B, 33 luminal B + HER-2, 10 HER-2 enriched, and 32 triple negative (TNBC). Luminal A and HER-2 enriched BC patients were excluded from the analysis due to the small sample size. pCR after NAC was achieved in 47 patients (41.2%). [18F]FDG PET/CT detected the primary tumor in 98.3% of patients and lymph node metastases were more frequently detected in Luminal B subgroup. Among Luminal B patients, median SUVmean_B values were significantly higher (p = 0.027) in responders (7.06 ± 5.9) vs. non-responders (4.4 ± 2.1) to NAC. Luminal B + HER-2 non-responders showed a statistically significantly higher median MTV_B (7.3 ± 4.2 cm3 vs. 3.5 ± 2.5 cm3; p = 0.003) and TLG_B (36.5 ± 24.9 vs. 18.9 ± 17.7; p = 0.025) than responders at baseline [18F]FDG PET/CT. None of the semiquantitative parameters predicted pCR after NAC in TNBC patients. However, among TNBC patients who achieved pCR after NAC, 4 volumetric parameters (MTV_B, TLG_B, MTV_WB and TLG_WB) were significantly higher in patients dead at follow-up. If confirmed in further studies, these results could open up a widespread use of [18F]FDG PET/CT as a baseline predictor of response to NAC in luminal B and luminal B + HER-2 patients and as a prognostic tool in TNBC." @default.
• W4310989660 created "2022-12-22" @default.
• W4310989660 creator A5000297270 @default.
• W4310989660 creator A5006530528 @default.
• W4310989660 creator A5009174566 @default.
• W4310989660 creator A5014978519 @default.
• W4310989660 creator A5016594495 @default.
• W4310989660 creator A5017138113 @default.
• W4310989660 creator A5020586666 @default.
• W4310989660 creator A5023860963 @default.
• W4310989660 creator A5062142605 @default.
• W4310989660 creator A5065609860 @default.
• W4310989660 creator A5079714288 @default.
• W4310989660 creator A5087431312 @default.
• W4310989660 creator A5087857567 @default.
• W4310989660 creator A5089013882 @default.
• W4310989660 date "2022-11-29" @default.
• W4310989660 modified "2023-10-14" @default.
• W4310989660 title "The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer" @default.
• W4310989660 cites W12086493 @default.
• W4310989660 cites W1495375466 @default.
• W4310989660 cites W1985650368 @default.
• W4310989660 cites W1985862706 @default.
• W4310989660 cites W1990185598 @default.
• W4310989660 cites W1999463736 @default.
• W4310989660 cites W2088783247 @default.
• W4310989660 cites W2117775530 @default.
• W4310989660 cites W2118611962 @default.
• W4310989660 cites W2128458647 @default.
• W4310989660 cites W2156681954 @default.
• W4310989660 cites W2256628135 @default.
• W4310989660 cites W2309067861 @default.
• W4310989660 cites W2766525994 @default.
• W4310989660 cites W2771390751 @default.
• W4310989660 cites W2774580734 @default.
• W4310989660 cites W2802542721 @default.
• W4310989660 cites W2896656670 @default.
• W4310989660 cites W2917837889 @default.
• W4310989660 cites W2949092068 @default.
• W4310989660 cites W2966007643 @default.
• W4310989660 cites W3095431940 @default.
• W4310989660 cites W3107340755 @default.
• W4310989660 cites W3126786489 @default.
• W4310989660 cites W3139109547 @default.
• W4310989660 cites W4211123279 @default.
• W4310989660 cites W4214901572 @default.
• W4310989660 cites W4220909654 @default.
• W4310989660 cites W4220990369 @default.
• W4310989660 cites W4221082307 @default.
• W4310989660 cites W4226183403 @default.
• W4310989660 cites W4241062183 @default.
• W4310989660 cites W4283030645 @default.
• W4310989660 cites W4296830146 @default.
• W4310989660 cites W4303613811 @default.
• W4310989660 cites W4308720354 @default.
• W4310989660 cites W854484239 @default.
• W4310989660 doi "https://doi.org/10.3390/cancers14235869" @default.
• W4310989660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36497351" @default.
• W4310989660 hasPublicationYear "2022" @default.
• W4310989660 type Work @default.
• W4310989660 citedByCount "6" @default.
• W4310989660 countsByYear W43109896602023 @default.
• W4310989660 crossrefType "journal-article" @default.
• W4310989660 hasAuthorship W4310989660A5000297270 @default.
• W4310989660 hasAuthorship W4310989660A5006530528 @default.
• W4310989660 hasAuthorship W4310989660A5009174566 @default.
• W4310989660 hasAuthorship W4310989660A5014978519 @default.
• W4310989660 hasAuthorship W4310989660A5016594495 @default.
• W4310989660 hasAuthorship W4310989660A5017138113 @default.
• W4310989660 hasAuthorship W4310989660A5020586666 @default.
• W4310989660 hasAuthorship W4310989660A5023860963 @default.
• W4310989660 hasAuthorship W4310989660A5062142605 @default.
• W4310989660 hasAuthorship W4310989660A5065609860 @default.
• W4310989660 hasAuthorship W4310989660A5079714288 @default.
• W4310989660 hasAuthorship W4310989660A5087431312 @default.
• W4310989660 hasAuthorship W4310989660A5087857567 @default.
• W4310989660 hasAuthorship W4310989660A5089013882 @default.
• W4310989660 hasBestOaLocation W43109896601 @default.
• W4310989660 hasConcept C121608353 @default.
• W4310989660 hasConcept C126322002 @default.
• W4310989660 hasConcept C126838900 @default.
• W4310989660 hasConcept C143998085 @default.
• W4310989660 hasConcept C199374082 @default.
• W4310989660 hasConcept C2775842073 @default.
• W4310989660 hasConcept C2776694085 @default.
• W4310989660 hasConcept C2777415128 @default.
• W4310989660 hasConcept C2777649267 @default.
• W4310989660 hasConcept C2778292576 @default.
• W4310989660 hasConcept C2779013556 @default.
• W4310989660 hasConcept C2780110267 @default.
• W4310989660 hasConcept C2780283643 @default.
• W4310989660 hasConcept C2780849966 @default.
• W4310989660 hasConcept C2989005 @default.
• W4310989660 hasConcept C530470458 @default.
• W4310989660 hasConcept C71924100 @default.
• W4310989660 hasConceptScore W4310989660C121608353 @default.
• W4310989660 hasConceptScore W4310989660C126322002 @default.
• W4310989660 hasConceptScore W4310989660C126838900 @default.

• next